Emerging immunotherapies for renal cell carcinoma
Identifieur interne : 000579 ( France/Analysis ); précédent : 000578; suivant : 000580Emerging immunotherapies for renal cell carcinoma
Auteurs : B. Escudier [France]Source :
- Annals of oncology [ 0923-7534 ] ; 2012.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Vaccin.
English descriptors
- KwdEn :
Abstract
In recent years, an improved understanding of renal cell carcinoma (RCC) tumour biology has resulted in major advances in the treatment of patients with metastatic RCC (mRCC). Although immunotherapy with interleukin-2 and interferon-a was once the standard of care for mRCC, the introduction of novel agents targeting angiogenesis and signal transduction pathways has markedly improved patient outcomes. However, targeted agents rarely induce complete responses, and patients eventually develop resistance to therapy, prompting consideration of novel therapeutic approaches and a resurgence of interest in immunotherapy for RCC. Phase I/II trials of vaccination with allogeneic dendritic cell/tumour fusions in patients with mRCC have demonstrated immunological and clinical responses in some patients, and T-cell modulating agents (e.g. antibodies against programmed death 1 and cytotoxic T lymphocyte-associated antigen-4, or soluble lymphocyte activation gene-3) and dendritic cell-activating toll-like receptor agonists have also shown encouraging evidence of efficacy in early-phase clinical trials. These early studies suggest that immunotherapy may continue to be an effective approach for patients with mRCC. As such, a number of other strategies are currently under investigation, including adoptive cell transfer (ACT) with T cells modified to target proteins expressed by renal tumours such as MAGE-A3/12, DR4 and TRAIL, and ACT with autologous natural killer cells. Results from trials of novel immunotherapies are encouraging, with data from other indications helping to facilitate development. To realise the full benefit for patients, it is likely that immunotherapy will need to be combined with targeted agents or other agents. Novel therapies used in combination or sequentially have the potential to improve outcomes in mRCC, and results from ongoing/planned trials will shape future therapy.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 003805
- to stream PascalFrancis, to step Curation: 001716
- to stream PascalFrancis, to step Checkpoint: 003710
- to stream Main, to step Merge: 009996
- to stream Main, to step Curation: 009323
- to stream Main, to step Exploration: 009323
- to stream France, to step Extraction: 000579
Links to Exploration step
Pascal:12-0376366Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Emerging immunotherapies for renal cell carcinoma</title><author><name sortKey="Escudier, B" sort="Escudier, B" uniqKey="Escudier B" first="B." last="Escudier">B. Escudier</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medical Oncology, Institut Gustave-Roussy</s1><s2>Villejuif/Paris-Sud</s2><s3>FRA</s3><sZ>1 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Villejuif/Paris-Sud</wicri:noRegion><wicri:noRegion>Institut Gustave-Roussy</wicri:noRegion><wicri:noRegion>Villejuif/Paris-Sud</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">12-0376366</idno><date when="2012">2012</date><idno type="stanalyst">PASCAL 12-0376366 INIST</idno><idno type="RBID">Pascal:12-0376366</idno><idno type="wicri:Area/PascalFrancis/Corpus">003805</idno><idno type="wicri:Area/PascalFrancis/Curation">001716</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003710</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">003710</idno><idno type="wicri:doubleKey">0923-7534:2012:Escudier B:emerging:immunotherapies:for</idno><idno type="wicri:Area/Main/Merge">009996</idno><idno type="wicri:Area/Main/Curation">009323</idno><idno type="wicri:Area/Main/Exploration">009323</idno><idno type="wicri:Area/France/Extraction">000579</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Emerging immunotherapies for renal cell carcinoma</title><author><name sortKey="Escudier, B" sort="Escudier, B" uniqKey="Escudier B" first="B." last="Escudier">B. Escudier</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medical Oncology, Institut Gustave-Roussy</s1><s2>Villejuif/Paris-Sud</s2><s3>FRA</s3><sZ>1 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Villejuif/Paris-Sud</wicri:noRegion><wicri:noRegion>Institut Gustave-Roussy</wicri:noRegion><wicri:noRegion>Villejuif/Paris-Sud</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Annals of oncology</title><title level="j" type="abbreviated">Ann. oncol.</title><idno type="ISSN">0923-7534</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Annals of oncology</title><title level="j" type="abbreviated">Ann. oncol.</title><idno type="ISSN">0923-7534</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adoptive cell immunotherapy</term><term>Carcinoma</term><term>Grawitz tumor</term><term>Kidney cancer</term><term>Malignant tumor</term><term>Modulation</term><term>T-Lymphocyte</term><term>Treatment</term><term>Vaccine</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Traitement</term><term>Hypernéphrome</term><term>Cancer rein</term><term>Tumeur maligne</term><term>Vaccin</term><term>Lymphocyte T</term><term>Modulation</term><term>Carcinome</term><term>Immunothérapie cellulaire adoptive</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In recent years, an improved understanding of renal cell carcinoma (RCC) tumour biology has resulted in major advances in the treatment of patients with metastatic RCC (mRCC). Although immunotherapy with interleukin-2 and interferon-a was once the standard of care for mRCC, the introduction of novel agents targeting angiogenesis and signal transduction pathways has markedly improved patient outcomes. However, targeted agents rarely induce complete responses, and patients eventually develop resistance to therapy, prompting consideration of novel therapeutic approaches and a resurgence of interest in immunotherapy for RCC. Phase I/II trials of vaccination with allogeneic dendritic cell/tumour fusions in patients with mRCC have demonstrated immunological and clinical responses in some patients, and T-cell modulating agents (e.g. antibodies against programmed death 1 and cytotoxic T lymphocyte-associated antigen-4, or soluble lymphocyte activation gene-3) and dendritic cell-activating toll-like receptor agonists have also shown encouraging evidence of efficacy in early-phase clinical trials. These early studies suggest that immunotherapy may continue to be an effective approach for patients with mRCC. As such, a number of other strategies are currently under investigation, including adoptive cell transfer (ACT) with T cells modified to target proteins expressed by renal tumours such as MAGE-A3/12, DR4 and TRAIL, and ACT with autologous natural killer cells. Results from trials of novel immunotherapies are encouraging, with data from other indications helping to facilitate development. To realise the full benefit for patients, it is likely that immunotherapy will need to be combined with targeted agents or other agents. Novel therapies used in combination or sequentially have the potential to improve outcomes in mRCC, and results from ongoing/planned trials will shape future therapy.</div></front></TEI><affiliations><list><country><li>France</li></country></list><tree><country name="France"><noRegion><name sortKey="Escudier, B" sort="Escudier, B" uniqKey="Escudier B" first="B." last="Escudier">B. Escudier</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000579 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000579 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= France
|étape= Analysis
|type= RBID
|clé= Pascal:12-0376366
|texte= Emerging immunotherapies for renal cell carcinoma
}}
| This area was generated with Dilib version V0.6.38. |  |